MSH5

MSH5 rs3131379 — An Immune Sentinel in the HLA Class III Region

The chromosome 6p21.33 locus is one of the most gene-dense and immunologically consequential stretches in the human genome. Wedged between the classical HLA genes and the complement cascade genes C2 and CFB lies the HLA class III region | The central segment of the major histocompatibility complex, encoding complement proteins, heat shock proteins, cytokines like TNF-α, and DNA repair enzymes — an evolutionary hub for immune function, and within it, MSH5 (MutS Homolog 5). MSH5 is a DNA mismatch repair protein that forms an obligate heterodimer with MSH4 and plays a specialized role in two critical immune processes: meiotic crossover and immunoglobulin class-switch recombination | Class-switch recombination is the molecular process by which B cells swap immunoglobulin constant regions, changing from IgM to IgG, IgA, or IgE antibodies; MSH5/MSH4 ensures this DNA rearrangement proceeds through classical repair rather than error-prone microhomology pathways. The rs3131379 variant is an intronic SNP that tags a broader haplotype block carrying risk for systemic lupus erythematosus, with documented epistatic interactions with both IRF5 and CTLA4 — two of the most important non-HLA autoimmune susceptibility genes.

The Mechanism

Rs3131379 lies within an intron of MSH5 and does not itself alter protein sequence. Its biological significance comes from its position as a haplotype tag | A variant in strong linkage disequilibrium with one or more functional variants; genotyping rs3131379 effectively captures the disease-associated haplotype even without knowing the precise causal change for an HLA class III risk haplotype. The A allele marks a chromosomal block containing the complement factor B locus (CFB), C2, and flanking regulatory elements that influence both innate immune complement activation and type I interferon tone. Functional evidence shows that rs3131379 contributes to IFN-α production | Type I interferons are antiviral cytokines that also drive lupus pathology when chronically elevated; the rs3131379 A allele increases TLR7/8- and TLR9-dependent IFN-α and IFN-β responses in peripheral leukocytes by peripheral leukocytes stimulated through Toll-like receptors 7, 8, and 9 — the same innate immune receptors implicated in lupus pathogenesis through sensing endogenous nucleic acids released from dying cells.

At the molecular level, MSH5 dysfunction impairs immunoglobulin class switching. When MSH5 is working optimally, B cells switch efficiently from IgM to downstream isotypes (IgG, IgA, IgE) using classical DNA repair at the switch junctions. When MSH5 variants impair MSH4 binding — as documented for the L85F/P786S allele at this locus — switch joints accumulate increased microhomology-mediated repair errors | Alternative recombination that uses short regions of sequence similarity rather than canonical break-and-rejoin repair; this produces abnormal junction sequences and is elevated in patients with CVID and IgA deficiency, reducing IgA production efficiency. Patients with IgA deficiency and common variable immunodeficiency (CVID) are enriched for variants at this locus, though the MSH5 variant marks the HLA-DRB1*0102 haplotype rather than directly causing disease.

The Evidence

The strongest SLE-specific evidence comes from a landmark epistasis study by Hughes et al. (2012) examining 4,248 SLE patients and 3,818 healthy controls | All European ancestry; the largest published analysis of gene-gene interactions in SLE at the time of European descent. This analysis identified rs3131379 as producing the most significant gene-gene interaction in lupus genetics: the HLA region A allele at rs3131379 interacts with CTLA4 rs231775 with an interaction odds ratio of 1.19 (P = 7.8×10⁻⁵, FDR ≤0.05). The IRF5 interaction was also significant — carrying the rs3131379 A allele increased the odds of also carrying the IRF5 risk allele by 16% (P = 0.0047), suggesting co-segregation or selective pressure maintaining both risk haplotypes together.

Independently, Fernando et al. (2012) performed transancestral high-density mapping | Custom Illumina chip genotyping of the MHC region in 1,433 SLE cases and 1,458 controls from UK, Spanish, and Filipino populations of the entire MHC region in SLE and identified MSH5 as a new susceptibility locus independent of HLA-DRB1 alleles and other known HLA risk factors. This transancestral confirmation across three ancestry groups strengthens the causal attribution to the MSH5 region rather than treating it purely as LD with classical HLA alleles.

Functional validation came from a cardiovascular genetics study that incorporated SLE-derived SNPs to examine interferon regulation. Nelson et al. (2015) identified rs3131379 as one of three variants | The three-SNP panel: rs10516487 (TNFAIP3 region), rs3131379 (MSH5/HLA-III), and rs7574865 (STAT4) collectively account for 27.8% of variation in the CpG-oligonucleotide-induced IFN-α response forming a three-SNP genetic risk score that explains 27.8% of variation in TLR-dependent IFN-α production — the highest explained variance from any small SNP panel for this trait. Rs3131379 was associated with TLR7/8- and TLR9-dependent interferon responses, directly connecting the variant to the endosomal RNA/DNA sensing pathway that drives lupus nephritis and other organ manifestations.

A genome-wide association study of cutaneous lupus erythematosus | A subset of lupus presentations that primarily affects skin; shares HLA region risk architecture with systemic SLE further identified MHC region signals spanning MICA, MICB, MSH5, TRIM39, and RPP21, consistent with the MSH5 block being a genuine susceptibility region for lupus manifestations across tissue compartments.

Practical Implications

Carriers of the rs3131379 A allele, particularly heterozygotes (AG), should understand that this variant contributes to moderately elevated interferon tone and increased lupus susceptibility, but does not predetermine disease. The A allele is relatively common in European populations (~12%) and rare in East Asian populations (<0.1%), explaining some of the population-specific differences in SLE prevalence patterns. When the rs3131379 A allele co-occurs with IRF5 risk alleles (rs10488631-C or rs2004640-T), the combined effect exceeds either variant alone due to the documented epistatic amplification. Monitoring for lupus symptoms should be prioritized over passive observation when multiple risk alleles are present.

The IgA and antibody class-switching dimension of MSH5 adds a second clinical angle. People carrying A alleles at this locus may have modestly less efficient IgA production — potentially relevant to mucosal immunity, gut immune defense, and IgA nephropathy susceptibility — though this aspect requires further population-level study to quantify.

Interactions

The most important documented interaction is with IRF5 rs10488631. The Hughes 2012 epistasis study found that carrying the MSH5/HLA-III risk allele (rs3131379-A) increases the odds of also carrying the IRF5 risk haplotype (rs2070197, in LD with rs10488631-C) by approximately 16%. This co-occurrence amplifies type I interferon output beyond what either variant contributes independently. IRF5 drives interferon gene transcription while the HLA class III haplotype tagged by rs3131379 appears to lower the threshold for innate immune TLR activation through complement pathway dysregulation and MSH5-mediated effects on B cell antibody diversification.

The second major interaction is with CTLA4 rs231775. CTLA4 is a negative regulator of T cell activation; the rs231775 A allele reduces CTLA4 expression, allowing excessive T cell activation. The interaction OR of 1.19 between rs3131379 and CTLA4 rs231775 suggests that when both the innate immune arm (HLA class III / interferon) and the adaptive T cell arm (CTLA4 checkpoint failure) are genetically compromised, lupus risk compounds in a non-additive manner. This epistatic architecture implies that abatacept (a CTLA4-Ig fusion protein that mimics CTLA4 checkpoint function) might be particularly relevant for patients carrying both risk alleles.